glycyrrhizic acid has been researched along with 2019 Novel Coronavirus Disease in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 23 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X | 1 |
| Gowda, P; Joshi, SD; Kumawat, RK; Patrick, S; Sen, E | 2 |
| Bian, H; Xia, M; Xu, Y; Yang, X | 1 |
| He, S; Li, E; Li, J; Wang, L; Xu, D; Zhang, G; Zhang, M | 1 |
| Bellussi, LM; Ciprandi, G; Damiani, V; Passali, D | 1 |
| Fando, AA; Fomenko, VV; Karpenko, LI; Komarova, NI; Maksyutov, RA; Pokrovsky, AG; Pyankov, OV; Rogachev, AD; Rudometova, NB; Salakhutdinov, NF; Shcherbakov, DN; Yarovaya, OI; Zaykovskaya, AV | 1 |
| Zamzami, MA | 1 |
| Hussein, MA; Jain, R; Martens, C; Munirathinam, G; Pierce, S; Shahagadkar, P | 1 |
| Ahn, SJ; Chokkakula, S; Jeong, JH; Jung, JM; Jung, JW; Kim, BK; Kim, EG; Lee, WH; Min, SC; Oh, S; Park, JH; Park, OB; Song, MS | 1 |
| Feng, X; Jiang, Y; Liu, C; Qu, F; Xi, H; Zhao, X; Zhao, Y | 1 |
| Li, J; Liu, D; Luo, P | 1 |
| Bai, C; Chang, H; Guo, R; Leung, E; Li, P; Liu, H; Liu, T; Wang, J; Wang, Y; Wu, S; Yang, R; Zhang, X | 1 |
| Bailly, C; Vergoten, G | 1 |
| Chrzanowska, A; Chrzanowski, J; Graboń, W | 1 |
| Ding, H; Hu, Y; Li, H; Li, S; Tang, H; Zhai, S; Zhao, R | 1 |
| Huang, YX; Tang, YP; Wang, WX; Yue, SJ | 1 |
| Al-Kamel, H; Grundmann, O | 1 |
| Alt, M; Bormann, M; Dittmer, U; Elsner, C; Heilingloh, CS; Krawczyk, A; Schipper, L; Steinmann, E; Todt, D; van de Sand, L; Witzke, O | 1 |
| Abbasi, SW; Abro, A; Ahmad, S; Ismail, S; Waheed, Y | 1 |
| Beeg, M; Diomede, L; Fumagalli, O; Gamba, A; Gobbi, M; Salmona, M | 1 |
| Chen, J; Chen, M; Gan, W; Nie, Y; Tan, Y; Tian, X; Ying, R; Zhang, C | 1 |
| Chen, W; Hu, W; Liu, J; Qu, H; Tan, R; Xiang, X; Yang, Z | 1 |
9 review(s) available for glycyrrhizic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries | 2020 |
Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
Topics: Age Factors; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; COVID-19; COVID-19 Drug Treatment; Cytokines; Dipeptides; Gene Expression Regulation; Glucose; Glycyrrhizic Acid; Humans; Hypoxia; Liver; Lung; Non-alcoholic Fatty Liver Disease; Receptors, Virus; SARS-CoV-2; Severity of Illness Index | 2021 |
Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights.
Topics: Antineoplastic Agents; COVID-19; Glycyrrhiza; Glycyrrhizic Acid; Humans; Phytochemicals; Plant Extracts; Triterpenes | 2022 |
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Metabolism; Betacoronavirus; Cardiovascular Physiological Phenomena; Chloroquine; Congenital Abnormalities; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Susceptibility; Drug Combinations; Drug Delivery Systems; Female; Functional Residual Capacity; Glycyrrhizic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Interferon Type I; Lopinavir; Metformin; Nanoparticles; Oxygen Consumption; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Prognosis; Respiratory Physiological Phenomena; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Stillbirth; Ventilation-Perfusion Ratio | 2020 |
Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
Topics: Alarmins; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Glycyrrhizic Acid; Humans; Hydroxychloroquine; Membrane Microdomains; Molecular Docking Simulation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Tenofovir | 2020 |
Glycyrrhizin: An old weapon against a novel coronavirus.
Topics: Administration, Intranasal; Administration, Topical; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Chemoprevention; COVID-19; COVID-19 Drug Treatment; Glycyrrhizic Acid; Humans; Peptidyl-Dipeptidase A; SARS-CoV-2; Signal Transduction; Therapies, Investigational | 2021 |
The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS.
Topics: Anti-Inflammatory Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Glycyrrhizic Acid; Humans; Middle East Respiratory Syndrome Coronavirus; Pandemics; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Treatment Outcome | 2020 |
Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19).
Topics: COVID-19; COVID-19 Drug Treatment; Glycyrrhizic Acid; Humans; SARS-CoV-2 | 2021 |
Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?
Topics: Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Glycyrrhetinic Acid; Glycyrrhiza; Glycyrrhizic Acid; Humans; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virus Internalization | 2021 |
14 other study(ies) available for glycyrrhizic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Repurposing Methotrexate in Dampening SARS-CoV2-S1-Mediated IL6 Expression: Lessons Learnt from Lung Cancer.
Topics: A549 Cells; Adenocarcinoma of Lung; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Cell Line, Tumor; COVID-19; COVID-19 Drug Treatment; Cytokine Receptor gp130; Folate Receptor 2; Glycyrrhizic Acid; HMGB1 Protein; Humans; Immunosuppressive Agents; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Methotrexate; Phosphorylation; SARS-CoV-2; Spike Glycoprotein, Coronavirus; STAT3 Transcription Factor | 2022 |
Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; Binding Sites; COVID-19; COVID-19 Drug Treatment; Glycyrrhizic Acid; Humans; Molecular Docking Simulation; Protein Binding; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virus Internalization | 2021 |
HMGB1-antagonism exerted by glycyrrhizin could be fruitful against COVID-19.
Topics: COVID-19; Glycyrrhizic Acid; HMGB1 Protein; Humans; Pandemics; SARS-CoV-2 | 2021 |
Synthesis and In Vitro Study of Antiviral Activity of Glycyrrhizin Nicotinate Derivatives against HIV-1 Pseudoviruses and SARS-CoV-2 Viruses.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Glycyrrhizic Acid; HeLa Cells; HIV Infections; HIV-1; Humans; In Vitro Techniques; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |
Molecular docking, molecular dynamics simulation and MM-GBSA studies of the activity of glycyrrhizin relevant substructures on SARS-CoV-2 RNA-dependent-RNA polymerase.
Topics: Antiviral Agents; COVID-19; DNA-Directed RNA Polymerases; Glycyrrhizic Acid; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inhibitors; RNA, Viral; SARS-CoV-2 | 2023 |
Evaluation of the Antiviral Efficacy of Subcutaneous Nafamostat Formulated with Glycyrrhizic Acid against SARS-CoV-2 in a Murine Model.
Topics: Animals; Antiviral Agents; COVID-19; Disease Models, Animal; Glycyrrhizic Acid; Humans; Mice; Pandemics; Rats; Rats, Sprague-Dawley; SARS-CoV-2 | 2023 |
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Glycyrrhizic Acid; Humans; Interferons; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Reactive Oxygen Species; SARS-CoV-2; Virus Attachment; Virus Internalization | 2020 |
Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study.
Topics: Animals; Anti-Inflammatory Agents; Betacoronavirus; Cells, Cultured; Computer Simulation; Coronavirus Infections; COVID-19; Drugs, Chinese Herbal; Gene Expression; Glycyrrhizic Acid; Humans; Interleukin-6; Lipopeptides; Lipopolysaccharides; Male; Pandemics; Pneumonia; Pneumonia, Viral; Rats; SARS-CoV-2; Signal Transduction; Thrombin; Toll-Like Receptors | 2020 |
Drug repurposing for COVID-19: could vitamin C combined with glycyrrhizic acid be at play by the findings of Li et al.'s database-based network pharmacology analysis?
Topics: Ascorbic Acid; COVID-19; COVID-19 Drug Treatment; Databases, Pharmaceutical; Drug Repositioning; Glycyrrhizic Acid; Humans; SARS-CoV-2 | 2021 |
Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication.
Topics: A549 Cells; COVID-19; COVID-19 Drug Treatment; Glycyrrhizic Acid; HMGB1 Protein; Humans; SARS-CoV-2; Spike Glycoprotein, Coronavirus; U937 Cells; Viroporin Proteins; Virus Replication | 2021 |
Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease.
Topics: Animals; Antiviral Agents; Cell Survival; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19; Glycyrrhiza; Glycyrrhizic Acid; Humans; Peptide Hydrolases; Plant Extracts; Plant Roots; Protease Inhibitors; SARS-CoV-2; Vero Cells; Virus Replication | 2021 |
Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Antiviral Agents; Binding Sites; COVID-19; COVID-19 Drug Treatment; Drug Discovery; Drug Repositioning; Glycyrrhizic Acid; Host-Pathogen Interactions; Humans; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Receptors, Virus; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Structure-Activity Relationship; Virus Internalization | 2021 |
Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of anti-SARS-CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis.
Topics: Chemical and Drug Induced Liver Injury; China; COVID-19; Glycyrrhizic Acid; Humans; Meta-Analysis as Topic; Research Design; Retrospective Studies; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome | 2021 |
Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized COVID-19 patients: a retrospective, observational study.
Topics: Ascorbic Acid; COVID-19; Glycyrrhizic Acid; Humans; Retrospective Studies; SARS-CoV-2 | 2022 |